Literature DB >> 28810580

Connexin 43 enhances paclitaxel cytotoxicity in colorectal cancer cell lines.

Siqi Wang1, Shiwu Zhang2, Zhenying Zhao3, Chunze Zhang4, Xiaoyun Yang2, Yijia Wang1.   

Abstract

Colorectal cancer has a relatively low sensitivity to paclitaxel. The purpose of this study was to investigate the role of connexin 43 (Cx43), which is a structural component of gap junctional communication (GJC), in paclitaxel cytotoxicity in colorectal cancer cells. Three colorectal cancer cell lines (HCT106, HCT116 and LoVo) were transfected with Cx43 and used to examine paclitaxel cytotoxicity. A western blot assay was used to confirm Cx43 expression in transfected cell lines as well as the expression of several proteins that are associated with paclitaxel cytotoxicity. A parachute dye-coupling assay was used to measure GJC function. An MTT assay was used to analyze the viability of paclitaxel-treated cells. Cx43 expression level and GJC function were significantly upregulated by the transfection (P<0.05). The viability of transfected cells was significantly inhibited compared with that of untransfected cells when treated with paclitaxel (20 or 80 nM) at high culture density but not at low culture density (P<0.05). Cx43 transfection significantly increased the mitotic arrest, tubulin polymerization and apoptosis effects of paclitaxel (P<0.05). It was also found that paclitaxel had an inhibitory effect on GJC function after 12 h of treatment in LoVo cells (P<0.05). These results indicate that Cx43 may serve as a target of paclitaxel chemotherapy for colorectal cancer.

Entities:  

Keywords:  colorectal cancer; connexin 43; cytotoxicity; gap junctional communication; paclitaxel

Year:  2017        PMID: 28810580      PMCID: PMC5526126          DOI: 10.3892/etm.2017.4589

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  34 in total

Review 1.  Mechanisms of Taxol resistance related to microtubules.

Authors:  George A Orr; Pascal Verdier-Pinard; Hayley McDaid; Susan Band Horwitz
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

2.  Decreased gap junctional communication in neurobiotin microinjected lens epithelial cells after taxol treatment.

Authors:  Daniel Giessmann; Carsten Theiss; Winrich Breipohl; Karl Meller
Journal:  Anat Embryol (Berl)       Date:  2005-04-28

3.  Dose-dependent effects of stable cyclin B1 on progression through mitosis in human cells.

Authors:  Frank Wolf; Cornelia Wandke; Nina Isenberg; Stephan Geley
Journal:  EMBO J       Date:  2006-05-25       Impact factor: 11.598

Review 4.  Role of connexin genes in growth control.

Authors:  H Yamasaki; C C Naus
Journal:  Carcinogenesis       Date:  1996-06       Impact factor: 4.944

5.  The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression.

Authors:  F Li; D C Altieri
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

6.  Connexin43 acts as a colorectal cancer tumor suppressor and predicts disease outcome.

Authors:  Solveig Sirnes; Jarle Bruun; Matthias Kolberg; Ane Kjenseth; Guro E Lind; Aud Svindland; Andreas Brech; Arild Nesbakken; Ragnhild A Lothe; Edward Leithe; Edgar Rivedal
Journal:  Int J Cancer       Date:  2011-10-20       Impact factor: 7.396

Review 7.  Emerging roles of caspase-3 in apoptosis.

Authors:  A G Porter; R U Jänicke
Journal:  Cell Death Differ       Date:  1999-02       Impact factor: 15.828

8.  CTGF increases drug resistance to paclitaxel by upregulating survivin expression in human osteosarcoma cells.

Authors:  Hsiao-Chi Tsai; Chun-Yin Huang; Hong-Lin Su; Chih-Hsin Tang
Journal:  Biochim Biophys Acta       Date:  2014-01-23

9.  Pathological significance of connexin 26 expression in colorectal adenocarcinoma.

Authors:  Ran Hong; Sung-Chul Lim
Journal:  Oncol Rep       Date:  2008-04       Impact factor: 3.906

10.  Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43.

Authors:  J L Munoz; V Rodriguez-Cruz; S J Greco; S H Ramkissoon; K L Ligon; P Rameshwar
Journal:  Cell Death Dis       Date:  2014-03-27       Impact factor: 8.469

View more
  5 in total

1.  [Inhibitory effect of connexin43 protein on autophagy in cisplatin-resistant testicular cancer I-10 cells].

Authors:  Min Yuan; Shuying Dong; Yanxue Yao; Yunzheng Men; Kaijin Mao; Xuhui Tong
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-09-30

2.  The Potential Impact of Connexin 43 Expression on Bcl-2 Protein Level and Taxane Sensitivity in Head and Neck Cancers-In Vitro Studies.

Authors:  Bianka Gurbi; Diána Brauswetter; Attila Varga; Pál Gyulavári; Kinga Pénzes; József Murányi; Veronika Zámbó; Ede Birtalan; Tibor Krenács; David Laurence Becker; Miklós Csala; István Vályi-Nagy; István Peták; Kornél Dános
Journal:  Cancers (Basel)       Date:  2019-11-22       Impact factor: 6.639

Review 3.  Connexins-Therapeutic Targets in Cancers.

Authors:  Magdalena Nalewajska; Małgorzata Marchelek-Myśliwiec; Martyna Opara-Bajerowicz; Violetta Dziedziejko; Andrzej Pawlik
Journal:  Int J Mol Sci       Date:  2020-11-30       Impact factor: 5.923

4.  All-trans retinoic acid reverses epithelial-mesenchymal transition in paclitaxel-resistant cells by inhibiting nuclear factor kappa B and upregulating gap junctions.

Authors:  Guiling Shi; Xiaoli Zheng; Xiaojing Wu; Siqi Wang; Yijia Wang; Fei Xing
Journal:  Cancer Sci       Date:  2018-11-27       Impact factor: 6.716

5.  New Heterocyclic Combretastatin A-4 Analogs: Synthesis and Biological Activity of Styryl-2(3H)-benzothiazolones.

Authors:  Gjorgji Atanasov; Rusi I Rusew; Vladimir M Gelev; Christo D Chanev; Rosica Nikolova; Boris L Shivachev; Ognyan I Petrov; Margarita D Apostolova
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.